Antiamoebic drugs for treating amoebic colitis - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

Davila 2002 Methods Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: unclear; reported as “double-blind”, but blinding of participants, care provider, and outcome assessors not described Inclusion of all randomized participants: 100% Participants Number: 275 enrolled; 105/275 (38%) had E. histolytica or E. dispar infection (25 single infection and 80 mixed infection with other intestinal parasites)and were included in the review and analysed Inclusion criteria: children with stool specimens positive for E. histolytica/E. dispar and/or other intestinal parasites by direct smear or Kato-Katz technique Exclusion criteria: not stated Interventions 1. Nitazoxanide: 100 mg/5 mL twice daily orally for 3 days 2. Quinfamide: 100 mg/5 mL single oral dose; mebendazole 100 mg/5 mL twice daily orally for 3 days was added to quinfamide when another parasite other than E. histolytica/E. dispar was observed Not stated if placebo was used Outcomes 1. Parasitological cure: eradication of E. histolytica/E. dispar in stool examination 14 days after treatment 2. Adverse events: only tolerance to the drugs reported Data for parasitological cure were presented separately for nitazoxandie vs quinfamide for single infections and nitazoxanide vs quinfamide plus mebendazole for mixed infections, and included in a separate meta-analysis Notes Location: 3 communities in Colima, Mexico Date: 2002 (date of publication only; actual study period not reported) Source of funding: Instituto Mexicano del Seguro Social (IMSS); nitazoxanide was provided by Laboratories Columbia, S.A. de C.V., Mexico, D.F., Mexico Several attempts were made to contact the primary author, but they were not successful Donckaster 1964 Methods Generation of allocation sequence: random-numbers table Allocation concealment: unclear Blinding: unclear; reported as “double-blind”, but blinding of participants, care provider, and outcome assessors not described Inclusion of all randomized participants: 100% Participants Number: 346 enrolled; 346 analysed initially; 21 cases who failed after administration of the primary drugs were randomized a second time to receive a different drug and were analysed twice together with the first group Inclusion criteria: adults and children with clinical symptoms of intestinal amoebiasis and stool specimens positive for cysts and/or trophozoites of E. histolytica examined by the modified Telemann concentration technique (centrifugation with saline formol and ether) for cysts and the polyvinyl alcohol with fixative of Schaudin for the trophozoites Exclusion criteria: those without a source of potable water at home; unable to dispose of their excrement properly; or have other non-parasitic infections and are taking other medications for their infections Interventions 1. Dimethychlortetracycline: once daily on an empty stomach for 10 days at the following oral daily doses - children 15 mg/kg and adults 900 mg 2. Oxytetracycline: once daily on an empty stomach for 10 days at the following oral daily doses - children 25 mg/kg and adults 1500 mg 3. Tetracycline: once daily on an empty stomach for 10 days at the following oral daily doses - children 25 mg/kg Antiamoebic drugs for treating amoebic colitis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 37
Donckaster 1964 (Continued) and adults 1500 mg 4. Chlorphenoxamide: once daily after meals for 10 days at the following oral daily doses - children 125 mg for every 2 years of age and adults 1500 mg 5. Chlorbetamide: once daily after meals for 10 days at the following oral daily doses - children 100 mg/kg and adults 4000 mg 6. Racemic dehydroemetine: once daily after meals for 10 days at the following oral daily doses - children 5 mg for every 2 years of age and adults 40 mg 7. Diiodohydroxyquinoline: once daily after meals for 21 days at the following oral daily doses - children 200 mg for every 2 years of age and adults 1800 mg 8. Phenanthrondione: once daily after meals for 10 days at the following oral daily doses - children 25 mg for every 2 years of age and adults 300 mg 9. Bismuth glycoarsanilate: once daily after meals for 10 days at the following oral daily doses - children 250 mg for every 2 years of age and adults 2000 mg 10. Iodochlorhydroxyquinoline: once daily after meals for 21 days at the following oral daily doses - children 125 mg for every 2 years of age and adults 1000 mg 11. Placebo (starch): once daily after meals for 10 days at the following oral daily doses - children 250 mg for every 2 years of age and adults 1500 mg Not stated which among the drugs, if any, were identical in appearance to the placebo Outcomes 1. Parasitological failure: presence of cysts and/or trophozoites in the stool examinations done 10 and 40 days after start of treatment 2. Adverse events: voluntary reporting of clinical adverse events by participants every 3 days during treatment and every 10 to 15 days after treatment Notes Location: outpatient clinic of the University of Chile in Santiago, Chile Date: 1963 (date of publication only; actual study period not reported) Source of funding: not stated Huggins 1982 Methods Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: unclear; reported as “double-blind”, but blinding of participants, care provider, and outcome assessors not described Inclusion of all randomized participants: 100% Participants Number: 96 enrolled and analysed Inclusion criteria: adults with chronic intestinal amoebiasis and stool specimens positive for E. histolytica by direct smear with Lugol’s stain according to the Teleman-Richter or Hoffman, Pons, and Janer methods Exclusion criteria: not stated Interventions 1. Win 40.014 (quinfamide): 100 mg single oral dose 2. Win 40.014 (quinfamide): 100 mg twice a day orally at 12-hourly intervals for 1 day 3. Win 40.014 (quinfamide): 100 mg thrice a day orally at 8-hourly intervals for 1 day 4. Placebo: 300 mg daily dose orally, no information given on the frequency of administration of placebo Not stated if Win 40.014 (quinfamide)and placebo tablets were identical in appearance Antiamoebic drugs for treating amoebic colitis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 38
Page 1 and 2: Antiamoebic drugs for treating amoe
Page 3 and 4: Analysis 6.4. Comparison 6 Subgroup
Page 5 and 6: Authors’ conclusions Tinidazole i
Page 7 and 8: parasite RNA and DNA (Haque 1995; H
Page 9 and 10: histopathology. We included individ
Page 11 and 12: sponsored trials were conducted wit
Page 13 and 14: (WHO 1969) where ’cure’ was def
Page 15 and 16: Figure 1. Alternative drug vs metro
Page 17 and 18: ness or nausea. No abnormalities in
Page 19 and 20: 4.1. Single-dose secnidazole versus
Page 21 and 22: with some activity against cysts in
Page 23 and 24: A U T H O R S ’ C O N C L U S I O
Page 25 and 26: suspension (two days dosage) in the
Page 27 and 28: el tratamiento de ninos con amibias
Page 29 and 30: Murray 1980 {published data only} M
Page 31 and 32: Sankale 1969 {published data only}
Page 33 and 34: Dans 2006 Dans L, Martinez E. Amoeb
Page 35 and 36: associated with increased expressio
Page 37 and 38: Awal 1979 (Continued) Participants
Page 39: Botero 1977 (Continued) Exclusion c
Page 43 and 44: Kapadia 1968 Methods Generation of
Page 45 and 46: Mathur 1976 (Continued) Outcomes 1.
Page 47 and 48: Misra 1978 (Continued) 3. Adverse e
Page 49 and 50: Nnochiri 1967 (Continued) haemoglob
Page 51 and 52: Panggabean 1980 (Continued) Interve
Page 53 and 54: Prasad 1985 (Continued) years of ag
Page 55 and 56: Rossignol 2007 (Continued) Interven
Page 57 and 58: Singh 1977 (Continued) Outcomes 1.
Page 59 and 60: Swami 1977 (Continued) SGPT), and b
Page 61 and 62: (Continued) Baranski 1966 Not RCT B
Page 63 and 64: (Continued) Huggins 1969 Not RCT Hu
Page 65 and 66: (Continued) Padilla 2002 Interventi
Page 67 and 68: (Continued) Simjee 1985 Study popul
Page 69 and 70: Characteristics of studies awaiting
Page 71 and 72: 2 Parasitological failure: 1 to 14
Page 73 and 74: 2.3 Chlorhydroxyquinoline vs diiodo
Page 75 and 76: Comparison 9. Subgroup analyses: an
Page 77 and 78: (... Continued) Study or subgroup A
Page 79 and 80: Analysis 1.4. Comparison 1 Alternat
Page 81 and 82: Analysis 1.6. Comparison 1 Alternat
Page 83 and 84: Analysis 2.2. Comparison 2 Any anti
Page 85 and 86: Analysis 3.2. Comparison 3 Combinat
Page 87 and 88: Analysis 5.1. Comparison 5 Other an
Page 89 and 90: Analysis 6.1. Comparison 6 Subgroup
Page 91 and 92:
(... Continued) Study or subgroup A
Page 93 and 94:
Analysis 6.4. Comparison 6 Subgroup
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
(Continued) 24 - - chloroquine oxyt
Page 103 and 104:
(Continued) Department of Medicine,
Page 105 and 106:
(Continued) Africa Egypt Rossignol
Page 107 and 108:
(Continued) Stool microscopy plus s
Page 109 and 110:
(Continued) 6. Not used, but mentio
Page 111 and 112:
(Continued) Padilla 2000 Adequate U
Page 113 and 114:
(Continued) Misra 1974 Malaise: tin
Page 115 and 116:
(Continued) Pehrson 1984 ticipants)
Page 117 and 118:
(Continued) ; metronidazole (4 part
Page 119 and 120:
(Continued) Panidazole Botero 1977
Page 121 and 122:
(Continued) Appendix 12. Adverse ev
Page 123 and 124:
(Continued) Rossignol 2001 Rossigno
Page 125 and 126:
(Continued) Secnidazole vs quinfami
Page 127 and 128:
(Continued) idazole was encountered
Page 129 and 130:
(Continued) Combinationtinidazole a
Page 131 and 132:
(Continued) H I S T O R Y Protocol
Page 133:
Sensitivity analyses We intended to
show all

Antiamoebic drugs for treating amoebic colitis - The Cochrane Library

Create successful ePaper yourself

Delete template?

Save as template?